SNY

INMATE FLU SHOTS FOR 2026 FLU SEASON

THE NATIONAL SUPPLY SERVICE CENTER (NSSC), INDIAN HEALTH SERVICES (IHS), HAS A NEED FOR A LARGE QUANTITY OF INFLUENZA VACCINES FOR ANNUAL FLU IMMUNIZATION. THIS ANNUAL PURCHASE ENSURES THAT NSSC MAINTAINS SUFFICIENT QUANTITIES OF THE INFLUENZA VACCIN

FY26 M4 SANOFI PASTEUR FLU SHOTS APR 26

VACCINES FOR ADULTS EO 14398

FY26-27 PEDIATRIC COVID VACCINES EO 14398

FY26-27 ADULT COVID-19 VACCINES EO 14398

FALL 2026 FLU VACCINES B1 INMATES

FY26 INFUENZA VACCINES FOR STAFF AND INMATES AGAINST CONTRACT 36E79726D0009

EXTRACTABLE/LEACHABLE AND STABILITY STUDY TO SUPPORT LONG-TERM BULK STORAGE IN SINGLE-USE CONTAINERS.

INFLUENZA VIRUS VACCINES (2026-2027 SEASON) FOR THE STAFF/INMATE POPULATION OF FCI/FPC BECKLEY, WV

There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing.

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.

340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient

IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, drug pricing in federal programs, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. Issues around drug pricing. Education on vaccines.

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tarif

Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit.

Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patie